Corteva (CTVA) AI Stock Analysis

• Market Cap: $53.36B
• Dividend Yield: 1.04%
• Average Volume (3M): 4.09M
• Price to Earnings (P/E): 41.2
• Beta (1Y): 0.59
• Revenue Growth: 5.00%
• EPS Growth: 136.31%
• Country: US
• Employees: 22,000
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): 0.22
• Shares Outstanding: 672,524,000
• 10 Day Avg. Volume: 3,839,373
• 30 Day Avg. Volume: 4,092,410
• PEG Ratio: 1.80
• Price to Book (P/B): 1.87
• Price to Sales (P/S): 2.59
• P/FCF Ratio: 16.03
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 2.91
• Enterprise Value/Gross Profit: 6.26
• Enterprise Value/Ebitda: 16.46
• 1Y Price Target: $84.50
• Price Target Upside: 6.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): 3.64
• Revenue Forecast (FY): $18.10B

• Rating: 71 Outperform
• Price Target: $88.00 ▲(10.92% Upside)
• Action: Reiterated Date: 02/05/26
• Date: Action: Reiterated 02/05/26

The score is driven primarily by solid financial health (low leverage, improving margins, strong recent free cash flow) and a constructive earnings outlook with reiterated 2026 growth guidance and licensing/royalty tailwinds from the Bayer agreement. These positives are tempered by a rich valuation (high P/E, low yield) and technically overbought momentum, plus revenue inconsistency and pricing/tariff/FCF-normalization risks highlighted on the call.

Positive Factors

Strong free cash flow generation

Consistent, sizable free cash flow (~$2.9B in 2025 and historically 66%–83% of net income) underpins durable capital returns, reinvestment in R&D and product rollout, and cushions cyclical volatility. This strengthens strategic flexibility for buybacks, separation costs, and licensing execution.

Conservative balance sheet / low leverage

Very low leverage and sizable equity provide long-term financial resilience versus cyclicality in agriculture, enabling financing of separation, opportunistic M&A or sustained shareholder returns without jeopardizing credit standing. This structural strength reduces refinancing and solvency risks.

Bayer agreement accelerates licensing and reduces royalty risk

The Bayer settlement materially restructures long-term economics by accelerating licensing, reducing royalty drag and enabling earlier commercialization of platforms and U.S. cotton entry. This creates a durable revenue and margin tailwind beyond cyclical product sales and diversifies earnings via licensing streams.

Negative Factors

Stagnant / declining revenue trends

Persistent flat or falling revenue limits sustainable earnings growth and forces reliance on cost cuts, royalties, and one-time benefits to drive margins. Without durable top-line recovery, long-term profitability gains may be harder to maintain and are vulnerable to market share or acreage shifts.

Crop Protection pricing pressure and Brazil competition

Structural generics competition and import dynamics in Brazil, plus management guidance of low-single-digit CP price declines, threaten sustainable CP margins. Given CP’s contribution to near-term EBITDA, prolonged pricing pressure would erode profitability and returns on new product investments.

Earnings and FCF concentration and normalization risk

Reliance on unusually favorable working-capital timing and one-off items in 2025 makes cash generation less predictable. Separation costs and payment timing introduce multi-quarter swings, complicating capital allocation and weakening the sustainability of buybacks and dividend growth in medium term.

Corteva Business Overview & Revenue Model

Company Description

Corteva, Inc. operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics. This segment also provides digital solutions that assist farmer decision-making with a view to optimize product selection, and maximize yield and profitability. The Crop Protection segment offers products that protect against weeds, insects and other pests, and diseases, as well as enhances crop health above and below ground through nitrogen management and seed-applied technologies. This segment provides herbicides, insecticides, nitrogen stabilizers, and pasture and range management herbicides. It serves agricultural input industry. The company operates in the United States, Canada, Latin America, the Asia Pacific, Europe, the Middle East, and Africa. Corteva, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana.

How the Company Makes Money

Corteva primarily makes money by selling agricultural inputs to farmers, retailers, and distributors through two main revenue streams: 1) Seed (product sales plus trait and technology value) - Proprietary seed sales: Corteva generates revenue from selling branded seeds (notably Pioneer) across key row crops (e.g., corn and soybeans) and other crop categories. Revenue is driven by planted acres, product mix (premium hybrids/varieties), pricing, and regional demand. - Trait/technology value embedded in seed: A meaningful portion of seed revenue reflects the value of proprietary biotechnology traits (e.g., insect resistance, herbicide tolerance) that are integrated into Corteva’s seed offerings. - Licensing/royalties: Corteva also earns revenue by licensing certain seed traits/technologies to other seed companies and collecting associated fees/royalties where applicable. If specific counterparties or contract terms are not publicly detailed, null. 2) Crop Protection (crop chemicals and biologicals) - Product sales: Corteva sells crop protection solutions—herbicides, insecticides, fungicides, and certain biological offerings—earning revenue based on volumes sold, product mix (including differentiated, patented products), and pricing. Demand is influenced by pest and weed pressure, crop prices, planted acres, and regulation. - New product commercialization and lifecycle management: Earnings are supported by introducing new active ingredients/formulations and by extending the commercial life of existing products through new uses, formulations, or geographies. How revenue is realized and what influences earnings - Channel and geography: Sales are made through a mix of direct sales and agricultural retail/distributor channels across North America, Latin America, EMEA, and Asia-Pacific. Seasonality is significant, with sales concentrated around planting and in-season application windows. - Intellectual property (IP) and R&D: Corteva’s profitability is closely tied to generating and protecting IP (patented chemistries, proprietary germplasm, biotech traits) and monetizing it through premium pricing and/or licensing. - Manufacturing and supply chain: The company earns margins by producing and sourcing seed and crop protection products at scale, then selling them at prices reflecting differentiation and market conditions. - Partnerships/collaborations: Corteva participates in collaborations across the ag value chain (e.g., to develop, access, or distribute technologies). If specific material partnerships and their financial contribution are not publicly disclosed, null.

Corteva Financial Statement Overview

Summary

Strong financial foundation with low leverage and improved profitability and cash generation (2025 FCF ~$2.9B). The key offset is inconsistent/declining revenue in recent years, which raises durability risk despite margin gains.

Income Statement

Profitability improved meaningfully over the last two years, with gross margin rising from ~40% (2022) to ~46% (2025) and operating margin expanding to ~14% (2025). Net margin also recovered to ~6.3% (2025) from ~4.3% (2023). The key offset is top-line momentum: revenue has been flat-to-down recently (negative growth in 2023–2025, including a sharp drop in 2025), which limits overall earnings durability despite better margins.

Balance Sheet

The balance sheet is conservatively positioned with low leverage: debt-to-equity remains around ~0.10 (2025) and has been consistently modest across the period. Equity is sizable and stable, supporting financial flexibility. Returns are adequate but not strong—return on equity is in the mid-single digits (~4–5% in 2024–2025), suggesting the company is not currently generating high profitability relative to its capital base.

Cash Flow

Cash generation is a clear strength: operating cash flow and free cash flow are both solid and improved in 2024–2025, with free cash flow reaching ~$2.9B in 2025. Free cash flow has also consistently represented a large portion of net income (roughly ~66% to ~83% over 2023–2025), indicating good earnings quality. The main caution is volatility earlier in the period (notably weak 2022 free cash flow), implying cash conversion can swing with working capital and cycle dynamics.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	17.40B	16.91B	17.23B	17.45B	15.65B
Gross Profit	7.58B	7.38B	7.31B	7.02B	6.43B
EBITDA	3.07B	2.73B	2.54B	2.73B	3.62B
Net Income	1.09B	907.00M	735.00M	1.15B	1.76B
Balance Sheet
Total Assets	42.84B	40.83B	43.00B	42.62B	42.34B
Cash, Cash Equivalents and Short-Term Investments	4.53B	3.17B	2.74B	3.31B	4.54B
Total Debt	2.58B	2.70B	2.49B	1.31B	1.12B
Total Liabilities	18.46B	16.80B	17.72B	17.08B	16.72B
Stockholders Equity	24.14B	23.79B	25.04B	25.30B	25.38B
Cash Flow
Free Cash Flow	2.81B	1.55B	1.17B	267.00M	2.15B
Operating Cash Flow	3.41B	2.15B	1.77B	872.00M	2.73B
Investing Cash Flow	-543.00M	-589.00M	-1.99B	-632.00M	-362.00M
Financing Cash Flow	-1.64B	-1.20B	-99.00M	-1.18B	-1.27B

Corteva Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 79.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTVA, the sentiment is Positive. The current price of 79.34 is above the 20-day moving average (MA) of 78.24, above the 50-day MA of 74.52, and above the 200-day MA of 70.19, indicating a bullish trend. The MACD of 1.38 indicates Positive momentum. The RSI at 58.67 is Neutral, neither overbought nor oversold. The STOCH value of 79.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTVA.

Corteva Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CF	76 Outperform	$19.47B	8.62	29.95%	2.56%	12.59%	31.40%
CTVA	71 Outperform	$53.36B	41.25	4.40%	1.04%	5.00%	136.31%
MOS	68 Neutral	$8.82B	14.14	9.96%	3.70%	3.82%	239.39%
SMG	62 Neutral	$3.74B	-6.71	-27.23%	4.52%	-3.93%	―
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ICL	59 Neutral	$6.80B	32.61	3.77%	3.36%	1.77%	-8.72%
FMC	49 Neutral	$1.82B	-0.78	-61.24%	16.68%	-13.42%	-136.59%